Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. files periodic reports with the Securities and Exchange Commission as a publicly traded company listed on the New York Stock Exchange under ticker symbol BHC. The company also maintains a listing on the Toronto Stock Exchange. SEC filings provide detailed financial information, risk factors, business segment performance, and management discussion and analysis. Form 10-K annual reports offer comprehensive overviews of operations across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Quarterly Form 10-Q filings track financial performance throughout the fiscal year, breaking down revenue and profitability by therapeutic area and geographic region. Given the company's significant debt obligations, filings contain detailed disclosures regarding debt structure, maturity schedules, interest expenses, and refinancing activities. Form 8-K current reports disclose material events such as acquisitions, divestitures, executive changes, credit agreement amendments, and significant legal developments. Proxy statements (Form DEF 14A) provide information on corporate governance, executive compensation, board composition, and matters submitted for shareholder votes.
Patent litigation and intellectual property matters affecting key products like XIFAXAN receive disclosure in filings, as generic competition impacts future revenue streams. The company's relationship with Bausch + Lomb, in which it maintains a controlling interest, requires detailed segment reporting and potential disclosure of transactions between the entities. Regulatory compliance, manufacturing quality issues, and FDA enforcement actions would appear in SEC filings when material to investors. Debt covenant compliance, particularly given the company's leveraged capital structure, represents an important area of disclosure.
Investors use SEC filings to monitor trends in prescription volume, pricing dynamics, generic competition, research and development investments, and commercial strategy across therapeutic areas. Financial statements reveal capital allocation decisions, acquisition strategies, and operational efficiency across the diversified pharmaceutical portfolio. Risk factors sections outline threats including patent expirations, regulatory changes, reimbursement pressures, product liability, and competitive dynamics in pharmaceutical markets.
John Paulson, a director and the controlling person of Paulson Capital Inc., reported purchases of Bausch Health Companies common stock executed by funds he manages. The filings show three purchases: 2,000,000 shares at $6.35, 1,156,640 shares at $6.88, and 86,409 shares at $7.06, totaling 3,243,049 shares. After these transactions the reporting person’s indirect beneficial ownership is stated as 36,034,751 shares. The shares are held by managed funds and the report includes a disclaimer that the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. No derivative securities were reported on the form.
Bausch Health is asking shareholders to ratify a shareholder rights plan at a Special Meeting to be held via webcast on October 7, 2025 (record shareholders as of August 18, 2025 may vote). The Board adopted the Rights Plan on April 14, 2025 and issued one Right for each Voting Share outstanding at the Record Time. The Rights are intended to ensure all shareholders are treated equally in any unsolicited take-over bid and to discourage creeping acquisitions.
The Rights convert into purchase rights after a defined Separation Time if a person becomes an Acquiring Person (generally at a 20% Beneficial Ownership threshold). The Exercise Price is set at three times the 20-day average Market Price, and a Flip‑In Event can lead to significant dilution for an acquiror. The TSX has given conditional acceptance, and the Rights Plan requires reconfirmation by shareholders every third annual meeting to remain effective.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
